

RECEIVED  
PATENT  
APR 01 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Burke et al.

Group Art Unit: Not yet assigned

Serial No.: 09/998,718

Conf. No.: 7192

Filed: November 1, 2001

For: Methods and Compositions  
for Treatment of Ocular Neo-  
Vascularization and Neural Injury

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as First Class  
Mail in an envelope addressed to: Box Supplemental IDS-Non-  
Fee, Commissioner for Patents, Washington, D.C. 20231 on:

Date of Deposit: 3/25/2003

Person making Deposit: BONNIE FERGUSON

Signature: Bonnie Ferguson

Date of Signature: 3/25/2003

Examiner: Not yet assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

The reference listed on the attached Supplemental PTO-1449 form is being brought to the attention of the Examiner for consideration in connection with the examination of the above-captioned application.

Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

17400CIP(BAR)

Serial No. 09/998,718

2

PATENT

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO-1449 form with initials or other appropriate marks.


No fee is believed due in connection with this communication in accordance with 37 C.F.R. § 1.97(c) and 37 C.F.R. § 1.97(e). However, if Applicant is in error, please charge any fees that may be due in connection with this Information Disclosure Statement to Deposit Account No. 01-0885.

Respectfully Submitted,

Date:

3/21/03

Signature:



Carlos A. Fisher  
Registration No. 36,510  
ALLERGAN, INC.  
T2-7H  
Legal Department  
2525 Dupont Drive  
Irvine, CA. 92612  
Tel: (714) 246-4920  
Fax: (714) 246-4249

VED

APR 1 2003


Sheet 1 of 1

TECH JEN 1600/2900

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
FORM PTO-1449

## LIST OF REFERENCES CITED BY APPLICANT

|                                  |  |
|----------------------------------|--|
| ATTY. DOCKET:<br>17400CIP(BAR)   | SERIAL NO.: 09/998,718   |
| APPLICANT:<br>Burke et al        | TITLE: METHODS AND COMPOSITIONS FOR<br>TREATMENT OF OCULAR NEOVASCULARIZATION AND<br>NEURAL INJURY |
| FILING DATE:<br>November 1, 2001 | GROUP: Not Assigned  |



## U.S. PATENT DOCUMENTS

| *EXAMINER<br>INITIAL | DOCUMENT NO. | DATE | NAME | CLASS | SUB-CLASS | FILING DATE<br>(if applicable) |
|----------------------|--------------|------|------|-------|-----------|--------------------------------|
|                      |              |      |      |       |           |                                |

## FOREIGN PATENT DOCUMENTS

|    | DOCUMENT NO. | DATE       | COUNTRY | CLASS | SUB-CLASS | TRANSLATION<br>(yes/no) |
|----|--------------|------------|---------|-------|-----------|-------------------------|
| CA | WO 01 58240  | 8/16/2001  | PCT     |       |           |                         |
| CB | WO 01 74389  | 10/11/2001 | PCT     |       |           |                         |
| CC | WO 00 40245  | 7/13/2000  | PCT     |       |           |                         |
| CD | WO 0264163   | 8/22/2002  | PCT     |       |           |                         |

## OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

|    |  |
|----|--|
| CE | Ferrario et al, "Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma", Cancer Research, Vol. 60, No. 15, 8/1/2000, pgs. 4066-4069   |
| CF | Dimitroff et al, "Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy", Investigational New Drugs, 1999, 17(2), pgs. 121-135 |
| CG | Chang et al, "Corneal neovascularization", Vol. 12, No. 4, 8/2001, pgs. 242-249  |

EXAMINER \_\_\_\_\_

DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.